Improvement of dyspnoea following of six months treatment with tiotropium but not with salmeterol in patients with COPD

V. Brusasco, P. Thompson, W. Vincken, A. Lee, L. Towse, T. J. Witek (Genova, Italy; Nedlands, Australia; Brussels, Belgium; Bracknell, United Kingdom; Ridgefield, United States Of America)

Source: Annual Congress 2001 - COPD
Session: COPD
Session type: Poster Discussion
Number: 286
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Brusasco, P. Thompson, W. Vincken, A. Lee, L. Towse, T. J. Witek (Genova, Italy; Nedlands, Australia; Brussels, Belgium; Bracknell, United Kingdom; Ridgefield, United States Of America). Improvement of dyspnoea following of six months treatment with tiotropium but not with salmeterol in patients with COPD. Eur Respir J 2001; 16: Suppl. 31, 286

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 88s
Year: 2004

Effectiveness of indacaterol and tiotropium in patients with severe dyspnoea
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012


QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

Predicting factors for an exacerbation in patients with COPD during one year treatment with salmeterol/fluticasone or salmeterol
Source: Eur Respir J 2004; 24: Suppl. 48, 512s
Year: 2004

Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Improvements in FEV1 and symptoms in poorly-reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003

Lung function and symptom improvement with fluticasone/salmeterol and ipratropium/albuterol in albuterol responsive and non-responsive COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 89s
Year: 2004

Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Bronchodilator efficacy of tiotropium in patients with mild COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006

Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


The effect of tiotropium in the treatment of patients with COPD
Source: Annual Congress 2010 - COPD: management
Year: 2010


Once-daily QVA149 improves symptom scores in patients with COPD
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009

Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


Sleep architecture in COPD patients during salmeterol versus tiotropium bromide treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 199s
Year: 2006

Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use
Source: Eur Respir J 2004; 24: Suppl. 48, 289s
Year: 2004